Use of 50-M Walk Test as a Tool to Assess Phase-1 Cardiovascular Rehabilitation after Acute Coronary Syndrome

Cristiane Maria Carvalho Costa Dias¹, Paula Luzia Seixas Pereira de Oliveira¹, Lilian Tapioca Jones Cunha Tapioca¹, Eloisa Pires Ferreira Prado¹, Francisco Thiago Oliveira de Oliveira¹, Luciana Bilitário Macedo¹ and Arnêmio Costa Quimarães²

¹Bahia School of Medicine and Public Health, Salvador, Bahia Brazil
²Federal University of Bahia, Salvador, Bahia Brazil

*Corresponding author: Cristiane Maria Carvalho Costa Dias, Bahia School of Medicine and Public Health, Salvador, Bahia Brazil, Tel: 55-71-99899544; E-mail: cmccdias@bahiana.edu.br; cristianedias7@yahoo.com.br

Received date: Jun 19, 2015; Accepted date: Aug 18, 2015; Published date: Aug 25, 2015

Copyright: ©2015 Dias, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Introduction: In 2009, Dias and colls made a contribution to this field by applying the first functional 50-M Walk Test (50MWT) in the Coronary Intensive care Unit (CICU), being able to direct the exercise prescription as well as evaluate the response to a cardiovascular rehabilitation program during hospitalization. As the Cardiovascular Rehabilitation Program 1 (CVR1) does not yet recommend the 50 MWT in CVR1 due to safety measures and cardiovascular repercussion on the program, the inclusion of this tool is necessary as it concerns a population at risk. Objective: Compare the functional response and cardiovascular 50 MWT in patients with ACS who underwent CVR1.

Methodology: Single-arm clinical trial, conducted with ACS patients admitted to the CICU of a private Hospital in Salvador - Brazil, from 24 to 48 hours post-event. The inclusion criteria consisted ACS patients with medical permission to walk, and had not been submitted to acute surgical treatments, aged ≥ 18 years who were oriented in time and space. Exclusion criteria included patients with orthopaedic problems, neurological sequelae and the inability to walk independently.

Results: A total of 66 patients were gathered to compare the response to tests before CVR1 and at the time of discharge; data of systolic arterial pressure (SBP), heart rate (HR), perceived exertion rate by the Borg Scale (BS), time and speed of walking were evaluated. Measurements were obtained in the supine, seated and orthostatic positions, at the end of the walk, after 5 minutes rest, and walking duration. Statistical significance for SBP, in the time of walking and BS was observed (p ≤ 0.05). HR presented no statistical significance; predominance was shown in the absence of adverse effects in 89.4% of patients.

Conclusion: This sample proved that patients who underwent CVR1 program presented an impact on functional capacity interpreted by an increase in walking speed, perceived exertion rate decreased and better blood pressure control during hospital discharge. Furthermore, 50 MWT might safely be applied as a tool before beginning CVR1, and as a method of assessing cardiovascular repercussion in the hospital stage after the program.

Keywords: Acute coronary syndrome; Rehabilitation; Motor activity; Gait; Effort test

Introduction

The acute coronary syndrome (ACS) is included among the cardiovascular diseases (CVDs) and comprises a condition that involves acute myocardial infarction (AMI) and unstable angina (AU) [1]. These correspond around 50% of male deaths with the projections made for the year 2020; CVDs will remain the leading cause of mortality and functional incapacity [2].

The therapeutic arsenal for these diseases consists of medications, surgery and cardiovascular rehabilitation [3,4]. The latter therapy comprises four phases: phase Cardiovascular Rehabilitation 1 (CVR1), initiated in a hospital environment, this first phase is the preparatory time for the following phases (II, III e IV) [5].

The prescription of bed rest for post-event patients hospitalized in the ICU, previously carried out, is an influential factor in the reduction of physical and cardiovascular capacity. As CVR1 is applied irrespective of the functional capacity of patients, with exercises being prescribed in accordance with the patient’s clinical stability and severity, this rehabilitation program described in the literature does not discuss the influence of cardio-circulatory variables on the functional capacity of patients with ACS undergoing cardiovascular rehabilitation at the hospital stage [6].

Gait is a complex ability, as it requires several controls of the posture and limb in order to produce dislocation of the body. It is known that with aging, the speed of gait tends to decrease due to physiological changes that occur, such as, reduction in muscle strength, increase in thoracic kyphosis and greater trunk flexion. Some authors have considered this reduction as a compensatory strategy of the body to generate greater stability, since there is a change in the center of gravity [7].

In 2009, Dias et al. made a contribution to this field by applying the first functional 50 m walk test (50MWT) in the coronary intensive care...
unit (CICU) in acute myocardial infarction patients after a period of 24 h, proving this method as safe and able to evaluate the cardiovascular stress after ACS. However, with this context, a gap was found in the literature regarding the functional evaluation of the population still in CICU. Thus, the inclusion of this test is necessary, because it is a population at risk. The evaluated variables were driving speed, perceived exertion rate and cardio-circulatory response. This study aims to compare the functional response and cardiovascular 50 MWT in patients with ACS who underwent CVR1 [8].

Methodology

It involved a single arm clinical trial (self-paired) to study patients diagnosed with ACS, treated with or without angioplasty, hospitalized in a private hospital in Salvador-BA, Brazil. Inclusion criteria included patients diagnosed with ACS, with medical permission to walk, and had not been submitted to surgical myocardial revascularization, over the age of 18 years, who were oriented in time and space. Exclusion criteria included individuals who continued to present symptoms of myocardial ischemia, HR>100 bpm, RF>28 ipm, SpO₂<92%, SBP<100 or>160 mmHg, DBP>100 mmHg; who had neurological and orthopedic dysfunctions, cognitive deficit and were incapable of walking independently [9].

Sample calculation was carried out based on an outcome variable, the HR as a continuous variable, qualitative, could serve as an indicator for assessing patient's functional response [10]. Standard deviation of HR during exercise: the estimate variation was from 70 to 100 bpm (considering that many of these patients used BB) and the value of SD=¼ of this variation (30÷4= ± 7.5 bpm). Standardized amplitude of the interval=total amplitude of the interval (4) ± SD (7.5)=0.53. N=minimum number of 62 patients.

Sample calculation was carried out based on an outcome variable, the HR as a continuous variable, qualitative, could serve as an indicator for assessing patient's functional response [10]. Standard deviation of HR during exercise: the estimate variation was from 70 to 100 bpm (considering that many of these patients used BB) and the value of SD=¼ of this variation (30÷4= ± 7.5 bpm). Standardized amplitude of the interval=total amplitude of the interval (4) ± SD (7.5)=0.53. N=minimum number of 62 patients.

The dependent variables were: SBP; HR; BS and walk duration. The statistic analyses were performed using the Statistical Package for the Social Sciences program (SPSS), version 14.0 for Windows. The Kolmogorov-Smirnov test was applied to analyze normality [16].
The results were presented through tables and figures, the categorical variables expressed in frequency values, such as sex, ACS classification, type of treatment, risk predictors and the time of 50MWT application after hospitalization. Analysis of continuous variables, all of which showed normal distribution, was expressed in mean and standard deviation (X ± SD). The chi-square test was used to compare the categorical variables. The Student paired T test was used to compare the mean of cardiocirculatory variables, perceived exertion rate and gait speed in two different moments - first and second 50MWT. The significance level assumed 5%.

The Research Ethics Committee of the Bahiana School of Medicine and Public Health, Protocol No. 170/2011 approved this study. The data of this study are primary, collected and used only for the effectiveness of this study's purpose, with patients free from any harm, particularly in regards to secrecy and confidentiality. Patients signed an informed consent and could withdraw their consent at any time, without any damage to them.

Table 1: Clinical characteristics and application of 50MWT in 66 patients with ACS before and after CVR1. SSA-Ba. 2013.

| Associated Risk factors | n (%) | p |
|-------------------------|-------|---|
| Sedentarism              | 38 (57.6) |   |
| Obesity/Overweight      | 38 (57.6) |   |
| Hypertension            | 45 (68.2) |   |
| Male Sex                | 45 (68.2) |   |
| Dyslipidemia            | 47 (71.2) |   |
| Smoking                 | 4 (6.1) |   |
| Diabetes mellitus       | 10 (152) |   |
| Application WT50m       | Mean (± SO) |   |
| Time after admission WT50m | 1.67 (± 0.84) |   |
| Time of hospitalization | 5.41 (± 2.44) |   |

Table 2 displays the behavior of physiological variables in the Gravitational Stress phase (Phase 1) and during the second time (after CVR1). When compared, the response of the first and second test showed a decline in systolic arterial pressure (SBP) even though the behavior of HR presented discrete variability in response to gravitational and physical stress, with variability in dorsal recumbent position Δ:0.74. As this was a high-risk population, patients were beta-blocked (51 [77.3%]) to the use of Tridil and anti-hypertensive medication 41 (62.1%), respectively.

In regards to the time variable in the 50MWT before and after CVR1, T1 (Pre) showed a mean of 1.17 (± 0.58) and T2 (Post) 0.89 (± 0.67). Thus presenting statistical significance p<0.02. Statistical analysis was performed of all cardiocirculatory variables of the research in comparison to the risk factors, and clinical characteristics of the sample, no significance was made notable.

Information extracted from the data such as distance - an immutable variable in the 50MWT performance; when combined with the time of walking, led to obtain the walking speed, also denominated as gait speed. This is represented in Figure 1, in which statistical significance was obtained, p<0.001, with speed amplification from 0.72 m/s to 0.92 m/s when 50MWT 1 was compared with 50MWT 2.

The perceived exertion rate was assessed by the Borg Scale (0-10), which when compared to the beginning of the tests (T1 and T2) increased by 3.1% of the domain "no effort", from 1.6% of "very, very light"; with a decrease of 1.5% of "light" and 3.0% of the domain "moderate", no statistical significance was shown. While the end of T1 in relation to T2 repeats the variability for the domain "very, very light", with an increase of 9.1% "very mild" and decrease of 4.5% for "light" and "moderate", with statistical significance of p<0.03 after physical stress.

No adverse effects were observed in the majority of the sample 59 (89.4%), with seven (10.5%) patients presenting adverse effects. These were described as three (4.5%) patients with hypotension, three (4.5%) with hypertension and only one (1.5%) with tachycardia; this occurred when all patients assumed the orthostatic position.

Discussion

This study showed that 50MWT is a tool that assesses the impact of functional response after RCV1 program in patients with ACS. The variables that were statistically significant SBP, gait speed and the perception of respiratory effort, regardless of application time of the first walk test and the length of hospital stay. Though hospital stay was brief, adaptation to cardiovascular system was possible by a reduction of double product and improvement of physical performance represented by the increase in gait speed.
The perceived exertion rate was evaluated by means of the modified Borg scale, an important instrument for evaluating the intensity of an activity as this prescription variable is individualized, and is related to cardiorespiratory and neuromuscular capacity. In this population, it was observed that after CVR1, lower frequency occurred of the domains that reflected the test, leading to greater subjective tiredness (“Moderate” and “Slight”) and amplification in reference to the three first domains of the Borg Scale. As for the study that described the test [8], the Borg scale was shown to be easy to apply, making it possible to evaluate the improvement in functional capacity. It is worth emphasizing that the perceived exertion rate was also influenced by psychological and not physiological factors only, thus making it difficult to define which variable was predominant [22].

In regards to cardiovascular risk factors associated in this population, no influence was demonstrated on the cardio-circulatory variables in response to the 1st and 2nd 50MWT. Nevertheless, it could be proved that in this sample there was no difference in the cardiovascular response to 50MWT according to the clinical classification. Although, the minimum age at which the coronary event occurred in this sample was lower than the estimated prevalence of ACD in adults over the age of 40 years [23], the demographic characteristics did not result in values differing from the cardiocirculatory variables when compared in isolated groups.

However the significant prevalence of 1°TC50m application period for 24-48 hours post coronary event, this result was more remarking that evidenced by Dias, 2009 [8], together with prevalence of hospital stay by seven days corroborating the average expected in the literature [24,25]. This sample is cautioned for a disease with a high cost to public health. This includes the direct costs in reference to medical interventions, and indirect costs, also known as social costs, which correspond to individual and family productivity loss, family members who have to provide care for the patient after event, as well as absenteeism and early mortality.

The adverse effects all succeeded on the assumption orthonostasis and 1°TC50m followed the earlier study profile [8]. The minority of the patients analysed, revealed a condition of hypotension, hypertension and tachycardia, making it necessary to interrupt the test, but as soon as they were re-stabilized, the CVR1 was resumed. This effect occurred in spite of patients having performed active lower limb exercises and respiratory exercises [26,27]. In the second test, these adverse effects did not occur, suggesting that after the progressive walk, the autonomic responses of patients improved. The authors pointed as a study limitation the absence of a control group.

Based on the result of this study, it was observed that patients who were submitted to the CVR1 program presented improved functional capacity, reflected by the increase in gait speed, lower perceived

---

Table 2: Physiological behavior variable SBP and HR in the gravitational stress and physical stress phase of the 50MWT before and after CVR1, in 66 patients with ACS. SSA-Ba, 2013.

| Variables          | SBP (mmHg) | HR (bpm) |
|--------------------|------------|----------|
|                    | Pre        | Post     | Δ        | value p | Pre        | Post     | Δ        | value p |
| D. Recumbent       | 137.34 (± 20.06) | 131.45 (± 19.04) | 5.89     | 0.01     | 73.08 (± 11.59) | 73.83 (± 11.62) | -0.74 | 0.56 |
| Rest Phase         | 131.58 (± 21.86) | 123.53 (± 17.83) | 8.01     | 0.01     | 75.19 (± 11.84) | 75.95 (± 12.31) | -0.75 | 0.15 |

In 2010, the 50MWT was considered the first functional test in the cardiology intensive care unit environment [7]. Until now, CVR1 patients were guided by programs pre-established by equivalent of metabolic consumption (METS) [8,15,17], therefore they were programs that did not respect patients individuality and previous functional capacity. The 50 m test enables a secure, individual progression based not only on nosological diagnosis, but mainly on the functional response of the patient.

When pressure response to 50MWT was evaluated following a CVR1 program, better pressure control was observed when compared to the first test. This result was also observed by Frazao and collaborators [16]. Differently from SBP, heart rate showed no adaptive effect at the end of the test. This finding may be justified by the short time of exposure to exercise. Studies have demonstrated that the effect of bradycardia induced by exercise occurs after six weeks [17]. Another aspect to be analysed is the discrete variability when exposed to gravitational and physical stress. This response is associated with the submaximal characteristic of the test, and use of beta-blockers [18].

Gait speed and BS is variables representative of functional performance. The first cited, presented a significant increase when in GS is maintained for one year it reduces the absolute risk of death in these individuals by 17.7%. As gait is a functional complex, the literature [20] has suggested gait speed to be the sixth most vital sign due to its immense reliability that translates in the individuality [21], reproduced in this study.

Variables
| Position       | SBP (mmHg) | HR (bpm) |
|----------------|------------|----------|
|                | Pre        | Post     | Δ        | value p | Pre        | Post     | Δ        | value p |
| D. Recumbent   | 137.34 (± 20.06) | 131.45 (± 19.04) | 5.89     | 0.01     | 73.08 (± 11.59) | 73.83 (± 11.62) | -0.74 | 0.56 |
| Rest Phase     | 131.58 (± 21.86) | 123.53 (± 17.83) | 8.01     | 0.01     | 75.19 (± 11.84) | 75.95 (± 12.31) | -0.75 | 0.15 |
exertion rate, and improved control of pressure on hospital discharge. Furthermore, the 50MWT was shown to be a safe tool capable of being used for evaluating and guiding the CVR1 program.

Acknowledgements

The author thanks the Hospital CardioPulmonar and its team for its receptiveness and permission to perform data collection, and thanks FAPESB for the scientific initiation scholarship No1490 /2012, and thanks to the Research Group GEPFIR for supporting the research.

The work was carried out in the Post-Graduation Program in Medicine and Human Health, Bahian School of Medicine and Public Health, Salvador (BA) Brazil.

References

1. dos Santos FL, de Araújo TL (2003) Having an infarction: the meanings of the disease from the patient’s perspective. Rev Lat Am Enfermagem 11: 742-748.
2. Aveuzum A, Piegas LS, Pereira JC (2005) Risk factors associated with acute myocardial infarction in the São Paulo metropolitan region: a developed region in a developing country. Arq Bras Cardiol 84: 206-213.
3. Lessa I (2003) Medical care and deaths due to coronary artery disease in Brazil, 1980-1999. Arq Bras Cardiol 81: 336-342, 329-35.
4. Stewart KJ, Badenhop D, Brubaker PH, Ketevian SJ, King M (2003) Cardiac rehabilitation following percutaneous revascularization, heart transplant, heart valve surgery, and for chronic heart failure. Chest 123: 2104-2111.
5. Cortez AA, Ferraz A, Nóbbega ACL, Brunetto AF, Herdy AH, et al. (2006) Diretriz de reabilitação cardiopulmonar e metabólica: aspectos práticos e responsabilidades. Arquivos Brasileiros de Cardiologia 86: 74-82.
6. Serrano C, Rocha e Silva M (2010) A review of cardiopulmonary research in Brazilian medical journals: clinical, surgical and epidemiological data. Clinics (Sao Paulo) 65: 441-445.
7. Abreu SSE, Caldas CP (2008) Velocidade de marcha, equilíbrio e idade: Um estudo correlacional entre idosas praticantes e idosas não praticantes de um programa de exercícios terapêuticos. Revista Brasileira de Fisioterapia 12: 320-330.
8. Dias CMCC, Maiato ACCA, Baqueiro KMM, Fiqueredo AMF, Rosa FW, et al. (2009) Resposta circulatória à caminhada de 50 m na unidade coronariana, na síndrome coronariana aguda. Arquivo Brasileiro Cardiologia 92: 132-142.
9. [No authors listed] (1997) [I National Consensus of Cardiovascular Rehabilitation]. Arq Bras Cardiol 69: 267-291.
10. Hulley SB, Cummings SR, Browner WS (2003) Delineando a pesquisa clínica: uma abordagem epidemiológica. Arq Bras Cardiol 95: 1-51.